Jaime Restrepo, Teobaldo Herrera, Rudiwilai Samakoses, Julio C Reina, Punnee Pitisuttithum, Angels Ulied, Linda-Gail Bekker, Edson D Moreira, Sven-Eric Olsson, Stan L Block, Luciano S Hammes, Fabio Laginha, Alex Ferenczy, Robert Kurman, Brigitte M Ronnett, Mark Stoler, Oliver Bautista, Nancy E Gallagher, Gino Salituro, Min Ye, Alain Luxembourg
BACKGROUND AND OBJECTIVES: The 9-valent human papillomavirus (9vHPV) vaccine Phase III immunogenicity study in 9- to 15-year-old boys and girls was extended to assess immunogenicity and effectiveness through 10 years after the last vaccine dose (NCT00943722). METHODS: Boys (n = 301) and girls (n = 971) who received three 9vHPV vaccine doses in the base study (day 1, months 2 and 6) enrolled in the extension. Serum was collected through month 126 for antibody assessments by competitive Luminex immunoassay and immunoglobulin G-Luminex immunoassay...
September 5, 2023: Pediatrics